WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

*Farah Ramzi Shareef, Nagham Ismael Ibrahim and Ameera Ahmed Mohammed

ABSTRACT

Background:The pathophysiology of preeclampsia has been extensively studied, yet significant problems remainunanswered. The diagnostic tools that are currently avai lable for early detecting preeclampsia are few therefore itis essential and crucial to investigate the possibility of developing a diagnostic technique that might detectpreeclampsia in pregnant before clinical symptoms appear. Objectives: Is to identify patients who are prone todevelop severe preeclampsia using soluble Endoglin, allowing for early intervention and better disease outcomesin Mosul City. Methods: This study is a prospective case-control study. Conducted at Mosul General Hospital between January 2021 to December 2023. The questionnaire was divided into three main sections. The first section provides demographic information about the study participants. The second section covers laboratory findings of the study participants. And section three for soluble endoglin level. Results : The study includes 150pregnant ladies , who were split into 100 preeclampsia groups, 50 severe PE versus 50 non severe PE, and 50normotensive women. Furthermore; the mean age of the study participants are 25.53 ± 5. 26 years, while; the meanof gestational ages of the study participants are 34.72 ± 4.37 weeks. Moreover; statistically significant differencebetween the study groups found regarding gestational age (P value <0.001) and abortion (P value=0.032).Additiona lly; statistically significant difference between the study groups found regarding gravity (more gravityfound among cases group), parity (more parity among cases group), abortion (more abortion among cases group).It’s evident that the soluble endoglin le vels increased as the severity of preeclampsia increased. In other word; themean levels were 1.72 ± 0.52 for non severe and 4.13 ± 2.34 for severe and 0.33 ± 0.13 for controls. Lastly; thestudy found that the optimum cut off points of endoglin for detect ing non severe and severe preeclampsia were0.86 ng/mL and 1.13 ng/mL. Conclusion: Soluble endoglin may be a new biomarker for determining the severityof preeclampsia, and greater research involving numerous centers and larger population is required for accuratelydetect the cut off value of soluble endoglin after which non severe and severe preeclampsia definitively occurred.